Question explored with the scientific record
Metformin for longevity
The evidence for metformin extending lifespan in healthy people is thin and indirect; the real-world data comes almost entirely from diabetic patients.
Nearly every study in this retrieval compares metformin to other diabetes drugs in people who already have type 2 diabetes. A 2021 meta-analysis of randomized trials in diabetics found a tendency toward lower all-cause mortality (odds ratio 0.71, p<0.05) but the confidence interval barely crossed significance [1]. A large 2015 retrospective study showed metformin users had lower mortality than sulfonylurea users, but that comparison tells you sulfonylureas may be worse, not that metformin is good for a healthy person [2].
The cancer evidence is mixed and observational. A 2010 meta-analysis reported about 31% lower cancer incidence in metformin-using diabetics, with strongest signals for pancreatic and liver cancer [4]. But a 2018 population study found no significant antitumor effect and even slight risk increases for lung and colorectal cancers [5]. The 2022 bladder cancer meta-analysis showed no reduction in incidence overall [3]. These are all diabetic populations, not healthy people.
Metformin has a real downside: it depletes vitamin B12. A 2012 study found biochemical B12 deficiency in 5.8% of metformin users over age 50, versus 2.4% in non-users [6]. B12 deficiency causes neuropathy, cognitive decline, and anemia. A multivitamin can partially correct this, but the drug still forces a nutritional cost [7].
The TAME trial (Targeting Aging with Metformin) was supposed to test metformin for longevity in non-diabetics, but it has not reported results. Without that trial, the entire longevity claim rests on extrapolation from sick populations.
My call: metformin may reduce mortality in diabetics, but there is no direct evidence it extends lifespan in healthy people, and it carries a real risk of B12 deficiency. Confidence: low for the longevity claim in non-diabetics.
Sources used 7
-
Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials
This updated meta-analysis evaluates the effects of metformin on all-cause mortality and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes, finding a significant association with lower risk of MACEs and a tendency towards reduced all-cause mortality co…
DOI: 10.1016/j.numecd.2020.11.031 -
ASSOCIATION BETWEEN FIRST-LINE THERAPY WITH SULFONYLUREA VERSUS METFORMIN AND RISK OF ALL-CAUSE MORTALITY: A RETROSPECTIVE STUDY
This study investigates the all-cause mortality rates in Type 2 diabetes mellitus patients treated with metformin versus sulfonylureas, finding significantly higher mortality in those treated with sulfonylureas.
DOI: 10.1016/s0735-1097(15)61412-7 -
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis
Metformin does not reduce overall bladder cancer incidence, but may improve certain oncologic outcomes after radical cystectomy in high-risk NMIBC/MIBC, though evidence is limited and biased.
DOI: 10.3233/blc-211653 -
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
A comprehensive systematic review and meta-analysis of observational studies examining metformin use in type 2 diabetic patients, showing about a 31% lower cancer incidence risk overall with strongest signals for pancreatic cancer and hepatocellular carcinoma, with some heteroge…
DOI: 10.1158/1940-6207.capr-10-0157 -
Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study
This observational population-based study investigates the effect of metformin and other glucose-lowering therapies on cancer incidence in patients with type 2 diabetes, finding no significant antitumor effect of metformin and suggesting a slight increase in risk for certain can…
DOI: 10.1016/j.diabres.2018.04.036 -
Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements
This study investigates the prevalence of biochemical B12 deficiency among U.S. adults aged 50 and older with type 2 diabetes on metformin compared to those not on metformin and those without diabetes, revealing a higher deficiency rate in metformin users and questioning the ade…
DOI: 10.2337/dc11-1582 -
The Effect of Multi-Vitamin/Multi-Mineral Supplementation on Nutritional Status in Older Adults Receiving Drug Therapies: A Double-Blind, Placebo-Controlled Trial
This study investigates the impact of a multivitamin-mineral supplement on the nutritional status of older adults taking diuretics, metformin, and/or proton pump inhibitors, finding significant improvements in serum folate, vitamin B12, and vitamin C levels after 16 weeks of sup…
DOI: 10.1080/19390211.2020.1834050